Accessibility Menu
InspireMD logo

InspireMD(NASDAQ) NSPR

Market Cap$30.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)-100%
5 Year-82%
1 Year-75%
1 Month-3%
$0.68
-0.92%
-0.01Today
InspireMD last closing stock price
MetricPriceDate
Last closeUSD 0.682026-08-03
InspireMD stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.23%USD 0.692026-07-27
1 month-2.58%USD 0.702026-07-02
3 month-38.09%USD 1.102026-05-05
Year to date-61.74%USD 1.782025-12-31
1 year-74.68%USD 2.692025-08-01
3 year-76.44%USD 2.892023-08-04
5 year-81.89%USD 3.762021-08-04
Since inception-100%USD 54,855,643.042011-04-11

InspireMD Financials at a Glance

Market Cap

$30.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$10.85M

Net Income (TTM)

-$37.33M

EPS (TTM)

-$0.74

P/E Ratio

-0.88

Dividend

$0.00

Beta (Volatility)

0.51 (Low)

Price

$0.68

Volume

39,041.407

Open

$0.67

Previous Close

$0.68

Daily Range

$0.65 - $0.70

52-Week Range

$0.63 - $2.93

Estimated Earnings Date

Aug 11, 2026

NSPR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InspireMD

InspireMD makes medical devices that help prevent strokes and heart attacks. Its main products use a fine mesh to keep blood vessels open and stop dangerous clots. These devices are used by doctors treating patients with blocked arteries in the neck or heart.

Products and Services

  • CGuard Carotid Stent: Mesh-covered stent for blocked neck arteries.
  • CGuard Prime: Updated stent for U.S. market, launched July 2025.
  • SwitchGuard Neuroprotection: Device in development to protect the brain during artery procedures.
  • PVGuard: Stent with mesh for leg arteries, still in development.
  • MGuard Prime: Stent for heart attack patients and bypass grafts, sold outside the U.S.

Growth and Expansion

  • Launched CGuard Prime in the U.S. in July 2025 after FDA approval.
  • Expanded U.S. headquarters and built a direct sales team in 2025.
  • Started manufacturing partnership with Aptyx Interventional Systems in 2025 to boost production.
  • Entered over 30 international markets since 2011, focusing on Europe and Asia Pacific.
  • Ongoing clinical trials for new uses, including stroke and leg artery disease, since 2024.

What Makes InspireMD Stand Out

The company’s mesh technology aims to lower the risk of stroke during artery procedures. Its products are sold through both direct sales in the U.S. and distributors abroad. InspireMD holds over 70 patents, supporting its position in a competitive market.

Five Things You Need to Know

  • Revenue was $8.98 million in 2025, up 28.1% from 2024.
  • Gross margin rose to 29.5% in 2025, up from 21.5% in 2024.
  • Operating loss was $49.61 million in 2025, up 48.1% from 2024.
  • Cash and marketable securities totaled $54.21 million at December 31, 2025.

Bottom Line

InspireMD has grown by expanding its product line and entering new markets. The company faces ongoing losses but continues to invest in innovation and global reach.

AI Generated • Apr 16, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

127

CEO

Marvin L. Slosman, MBA

Website

www.inspiremd.com

Headquarters

Miami, FL 33126, US

NSPR Financials

Key Financial Metrics (TTM)

Gross Margin

28.06%

Operating Margin

-480.57%

Net Income Margin

-344.13%

Return on Equity

-81.52%

Return on Capital

-83.97%

Return on Assets

-66.11%

Earnings Yield

-1.14%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$30.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

46.84M

Volume

39.04K

Avg. Volume

312.60K

Financials (TTM)

Gross Profit

$3.04M

Operating Income

-$52.13M

EBITDA

-$36.63M

Operating Cash Flow

-$38.65M

Capital Expenditure

-$1.50M

Free Cash Flow

-$40.15M

Cash & ST Invst.

$41.57M

Total Debt

$3.11M

InspireMD Performance Analysis

InspireMD annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,171,00015.0%
20232023-12-31USD 6,205,00020.0%
20242024-12-31USD 7,009,00013.0%
20252025-12-31USD 8,979,00028.1%
InspireMD sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3016.3%
Q32025-09-3041.9%
Q42025-12-3124.8%
Q12026-03-317.9%
InspireMD annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.3515.7%
20232023-12-31USD -0.82-65.1%
20242024-12-31USD -0.76-7.0%
20252025-12-31USD -0.76-0.6%
InspireMD sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-18.2%
Q32025-09-3034.6%
Q42025-12-3117.6%
Q12026-03-31102.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$3.40M

+122.2%

Gross Profit

$687.00K

+135.3%

Gross Margin

20.22%

N/A

Market Cap

$30.45MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$239.73K

N/A

Employees

127

N/A

Net Income

$289.00K

+102.6%

EBITDA

$438.00K

+104.0%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$41.57M

+59.4%

Total Debt

$3.11M

+33.9%

Accounts Receivable

$2.79M

+19.0%

Inventory

$3.04M

+7.6%

Long Term Debt

$2.04M

+24.6%

Short Term Debt

$1.07M

+56.2%

Return on Assets

-66.11%

N/A

Return on Invested Capital

-1.11%

N/A

Free Cash Flow

-$12.53M

-36.9%

Operating Cash Flow

-$12.34M

-40.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNTXContext Therapeutics Inc.
$0.60+0.78%
IMAImageneBio Inc
$5.64+1.62%
MBOTMicrobot Medical Inc.
$1.77+2.91%
HYPRHyperfine, Inc.
$0.98+4.85%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Questions About NSPR

What is the current price of InspireMD?

InspireMD is trading at $0.68 per share.

What is the 52-week range for InspireMD?

Over the past 52 weeks, InspireMD has traded between $0.63 and $2.93.

How much debt does InspireMD have?

As of the most recent reporting period, InspireMD reported total debt of $3.11M.

How much cash does InspireMD have on hand?

InspireMD reported $11.36M in cash and cash equivalents in its most recent financial results.

What is InspireMD’s dividend yield?

InspireMD does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services